Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

NZ to inoculate high-risk people first as COVID-19 vaccine gets full approval

Published 10/02/2021, 12:35 pm
Updated 10/02/2021, 12:36 pm

SYDNEY, Feb 10 (Reuters) - New Zealand will first administer COVID-19 vaccines to quarantine personnel, front line health workers and airline staff, COVID-19 Response Minister Chris Hipkins said, as the government formally approved its use on Wednesday.

New Zealand's medicines regulator last week provisionally approved the use of the COVID-19 vaccine jointly developed by U.S. drugmaker Pfizer Inc (NYSE:PFE) PFE.N and Germany's BioNTech 22UAy.DE .

"Now we've reached the crucial stage of approval for the first vaccine, we are in a much better position to start having a conversation with New Zealanders about how we plan to proceed," Hipkins said in a statement.

Authorities expect the Pfizer vaccine to arrive in the country by end-March but they had expressed concerns about export curbs. has been mounting on Prime Minister Jacinda Ardern to start inoculations for the country's 5 million people soon even though New Zealand has virtually eliminated the virus.

With just under 2,000 confirmed cases and 25 deaths since the pandemic began, New Zealand largely escaped the high number of cases and deaths from the virus compared with many other developed countries thanks to border closures and lockdowns.

But the emergence of highly contagious variants abroad and more overseas residents returning home has raised concerns of the virus spreading in the community again.

Ardern's critics have said New Zealand has fallen behind the rest of the world after promising in November that it would be first in the queue for COVID-19 vaccines.

"When the first batch of vaccine arrives, we will be ready to go," Hipkins said, adding information campaigns will begin next week.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

New Zealand will get 1.5 million vaccines from Pfizer, which will provide enough doses to vaccinate 750,000 people, while the medicines regulator is in talks with AstraZeneca (NASDAQ:AZN), Janssen and Novavax regarding the approval of their COVID-19 vaccines.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.